Loading…
Xenon Pharmaceuticals Inc. is projected to rise to $75.72 by 2027, a +18% move from its current price of $64.19. XENE is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/31/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 1 | $63.00 | $64.22 | $65.46 | +0.04% |
| Aug 2 | $62.52 | $64.24 | $66.01 | +0.08% |
| Aug 3 | $62.17 | $64.27 | $66.44 | +0.12% |
| Aug 4 | $61.88 | $64.29 | $66.81 | +0.16% |
| Aug 5 | $61.62 | $64.32 | $67.14 | +0.20% |
| Aug 6 | $61.39 | $64.35 | $67.44 | +0.24% |
| Aug 7 | $61.19 | $64.37 | $67.72 | +0.28% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $61.19 | $64.37 | $67.72 | +0.28% |
| Week 2 | $60.09 | $64.55 | $69.35 | +0.57% |
| Week 3 | $59.29 | $64.74 | $70.68 | +0.85% |
| Week 4 | $58.66 | $64.92 | $71.85 | +1.13% |
| Week 5 | $58.12 | $65.10 | $72.92 | +1.42% |
| Week 6 | $57.66 | $65.29 | $73.92 | +1.71% |
| Week 7 | $57.25 | $65.47 | $74.87 | +1.99% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Xenon Pharmaceuticals Inc. is a neuroscience-focused biopharmaceutical company that engages in the discovery, development, and delivery of therapeutics to treat patients with neurological and psychiatric disorders. Its product candidates include Azetukalner, a novel, potent Kv7 potassium channel opener which is in Phase 3 clinical development for the treatment of epilepsy, including focal onset seizures, and primary generalized tonic-clastic seizures, as well as neuropsychiatric disorders, such as major depressive disorder and bipolar depression.
The company has a license and collaboration agreement with Neurocrine Biosciences, Inc. for the development of NBI-921355, a Nav1.2/1.6 sodium channel inhibitor that is in Phase 1 clinical trials for the treatment of certain types of epilepsy. Xenon Pharmaceuticals Inc.
was incorporated in 1996 and is headquartered in Burnaby, Canada.
Xenon Pharmaceuticals Inc. trades under the symbol XENE. The stock currently sits at $64.94 and carries a market capitalization of $6.28B, with a ranking of 1164. The current price and market position place it among mid-cap biopharmaceuticals focusing on neurological and psychiatric conditions.
A major floor 30.5% below — a decisive break under it would weaken the trend.
The nearest floor, 17.6% below — buyers have tended to step in here.
The nearest ceiling, 10.5% above — a clean break opens room to run.
A major ceiling 25.8% above — clearing it would confirm fresh momentum.
Key XENE support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of XENE market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $64.69 | Sell | $64.57 | Sell |
| MA 10 | $65.61 | Sell | $65.11 | Sell |
| MA 20 | $66.02 | Sell | $64.40 | Sell |
| MA 50 | $59.02 | Buy | $60.93 | Buy |
| MA 100 | $57.81 | Buy | $57.03 | Buy |
| MA 200 | $50.02 | Buy | $51.77 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 52.53 | Neutral |
| Stoch RSI (14) | 16.07 | Buy |
| CCI (20) | -59.65 | Neutral |
| Williams %R (14) | -78.88 | Info |
| MACD (12,26,9) | -0.80 | Sell |
| ROC (12) | -4.62 | Sell |
| Bollinger %B (20,2) | 0.33 | Neutral |
| Stochastic %K (14) | 21.12 | Neutral |
| TRIX (15) | 0.60 | Buy |
| Awesome (5,34) | 2.99 | Buy |
| Ultimate (7,14,28) | 33.57 | Neutral |
| Momentum (10) | -2.79 | Sell |
| Aroon Osc (25) | 40.00 | Buy |
| Hull MA (9) | 63.78 | Buy |
| ADX (14) | 25.89 | Buy |
| ATR (14) | 1.06 | Info |
Technically, sentiment is bullish with an RSI of 60. The 50-day simple moving average sits at $58.27 while the 200-day simple moving average is $49.53. The stock trades with a nearby support at $51.99 and a nearby resistance at $70.96. Over the last 30 days, the price has ranged from a low of $56.88 to a high of $74.15. Annualized volatility stands at 40.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $39.98 | $64.19 | $85.50 | 0% | Neutral | |
| $62.02 | $75.72 | $96.64 | +18% | Neutral | |
| $66.04 | $82.20 | $107.84 | +28% | Bullish | |
| $82.82 | $104.71 | $140.37 | +63% | Bullish | |
| $96.12 | $123.21 | $168.22 | +92% | Bullish | |
| $107.14 | $139.05 | $192.91 | +117% | Bullish | |
| $116.21 | $152.56 | $214.72 | +138% | Bullish | |
| $115.55 | $153.33 | $218.66 | +139% | Bullish | |
| $130.10 | $174.39 | $251.71 | +172% | Bullish | |
| $150.08 | $203.12 | $296.50 | +216% | Bullish | |
| $207.95 | $293.82 | $449.80 | +358% | Bullish | |
| $440.33 | $668.32 | $1,097.78 | +941% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $39.98 | $64.19 | $74.78 | +0.00% |
| August 2026 | $56.71 | $66.14 | $78.62 | +3.03% |
| September 2026 | $56.77 | $66.59 | $79.92 | +0.69% |
| October 2026 | $56.20 | $66.24 | $80.10 | -0.53% |
| November 2026 | $57.43 | $67.95 | $82.67 | +2.59% |
| December 2026 | $58.87 | $69.89 | $85.50 | +2.85% |
Click any year to see its month-by-month XENE forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect XENE to range from $39.98 to $85.50 through 2026. The $64.19 average target implies a 0% move from current prices. A consolidation phase looks the most probable path here.
The XENE price prediction for 2027 points to an average of $75.72 (low $62.02, high $96.64) — a potential gain of +18% on today's $64.19. Price action looks broadly range-bound.
In 2028, XENE is projected to trade between $66.04 and $107.84, averaging $82.20 — a potential gain of +28% from today's $64.19. That is up +9% on the projected 2027 average. Buyers look set to stay in control over this stretch.
Xenon Pharmaceuticals Inc.'s 2029 outlook centres on $104.71, within a $82.82 to $140.37 range. That is up +27% on the projected 2028 average. That marks a +63% change versus current levels. Momentum favours further upside here.
By 2030, XENE could reach as high as $168.22, with a base case around $123.21 and support toward $96.12 — roughly +92% from $64.19. Buyers look set to stay in control over this stretch.
Expect XENE to range from $107.14 to $192.91 through 2031. The $139.05 average target implies a +117% move from current prices. That is up +13% on the projected 2030 average. Momentum favours further upside here.
The XENE price prediction for 2032 points to an average of $152.56 (low $116.21, high $214.72) — a potential gain of +138% on today's $64.19. Buyers look set to stay in control over this stretch.
In 2033, XENE is projected to trade between $115.55 and $218.66, averaging $153.33 — a potential gain of +139% from today's $64.19. That is up +1% on the projected 2032 average. Momentum favours further upside here.
Xenon Pharmaceuticals Inc.'s 2034 outlook centres on $174.39, within a $130.10 to $251.71 range. That is up +14% on the projected 2033 average. That marks a +172% change versus current levels. Buyers look set to stay in control over this stretch.
By 2035, XENE could reach as high as $296.50, with a base case around $203.12 and support toward $150.08 — roughly +216% from $64.19. Momentum favours further upside here.
Expect XENE to range from $207.95 to $449.80 through 2040. The $293.82 average target implies a +358% move from current prices. That is up +45% on the projected 2035 average. Buyers look set to stay in control over this stretch.
The XENE price prediction for 2050 points to an average of $668.32 (low $440.33, high $1,097.78) — a potential gain of +941% on today's $64.19. Momentum favours further upside here.
Investing $1,000 in XENE today (≈ 15.578751 XENE) could be worth
$10,411.63
+$9,411.63 (+941%) by 2050 · US Dollar
Based on the average projected XENE price of $668.32 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in XENEwould be worth at today's price.
$1,000 invested in XENE on Jul 30, 2025 (≈ 32.499187 XENE) would be worth
$2,086.12
+$1,086.12 (+108.6%) today · 2.09× · US Dollar
Based on a XENE entry price of $30.77 vs. today's $64.19.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $65.42 | $981.2 | -1.9% |
| 1 month ago | $60.36 | $1,063.45 | +6.3% |
| 3 months ago | $56.13 | $1,143.6 | +14.4% |
| 6 months ago | $41.01 | $1,565.23 | +56.5% |
| 1 year ago | $30.77 | $2,086.12 | +108.6% |
| All time (5.0y) ago | $17.58 | $3,651.31 | +265.1% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our XENE forecast.
Our base-case forecast reaches $130.00 around 2031.
Implied market cap at $130.00: $12.57B
The multi-year forecast shows meaningful upside beyond 2026. In 2026, the average price is $64.94 with a range of $39.98 to $87.07 and neutral sentiment. By 2027, the average price is $77.34 (min $63.15, max $99.18) with a 19.1% ROI and neutral sentiment.
The forecast accelerates into 2028 with an average of $84.81 (min $67.86, max $111.93) and 30.6% ROI, followed by 2029 with an average of $108.85 (min $85.66, max $146.93) and 67.6% ROI, and 2030 with an average of $128.41 (min $99.60, max $176.65) and 97.7% ROI, all with bullish sentiment. From 2031 onward, the projections show continued gains: 2031 average $145.49 (min $111.38, max $203.51) with 124% ROI, 2032 average $160.05 (min $121.05, max $227.26) with 146.5% ROI, and 2033 average $161.44 (min $120.72, max $232.37) with 148.6% ROI. The uptrend extends to 2034 average $184.91 (min $136.80, max $269.53) and 2035 average $216.23 (min $158.35, max $318.89), with 184.8% and 233% ROI respectively.
Looking further ahead, 2040 shows an average of $315.94 (min $221.05, max $489.52) and 386.5% ROI, while 2050 projects an average of $723.73 (min $469.22, max $1,206.20) and 1014.5% ROI, with bullish sentiment through the horizon. These figures illustrate a broad, upside trajectory but remain subject to market and clinical development risks.
Tap a question to reveal the answer.
In 2030, the forecast averages $128.41 with a range of $99.60 to $176.65 and a 97.7% ROI. The sentiment is bullish.
Forecasts show bullish sentiment from 2027 onward with growing average prices: 2027 average $77.34 (ROI 19.1%), 2028 $84.81 (30.6%), 2029 $108.85 (67.6%), 2030 $128.41 (97.7%), and beyond, though these are estimates and not guarantees.
Yes. The projections show max values above $200 in several years, including 2031 $203.51, 2032 $227.26, 2033 $232.37, 2034 $269.53, 2035 $318.89, 2040 $489.52, and 2050 $1,206.20.
The current price is $64.94 and the market cap is $6.28B.
The 30-day range is from $56.88 to $74.15. The stock shows bullish sentiment with RSI 60, SMA50 at $58.27, SMA200 at $49.53, a support level of $51.99, and a resistance at $70.96.
Xenon Pharmaceuticals Inc. Community Discussion
0Share your Xenon Pharmaceuticals Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.